Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Source: View publication →
In patients with previously treated, KRASG12C-mutated non-small-cell lung cancer, the selective KRASG12C inhibitor adagrasib demonstrated durable clinical activity with a manageable safety profile.
Key Findings
Study Design
Study Limitations
Clinical Significance
Adagrasib provides a targeted therapeutic option for a historically 'undruggable' mutation, KRASG12C, in NSCLC patients who have progressed on platinum-based chemotherapy and checkpoint inhibitors, addressing a critical area of unmet medical need.
Historical Context
KRAS mutations have long been considered 'undruggable' due to their high affinity for GTP and lack of clear binding pockets; however, the discovery of a druggable cysteine residue in the KRASG12C variant allowed for the development of covalent inhibitors like adagrasib following the initial proof-of-concept established by sotorasib.
Guided Discussion
High-yield insights from every perspective
Explain the molecular mechanism by which the KRAS G12C mutation leads to constitutive signaling and how adagrasib specifically interrupts this cycle.
Key Response
The G12C mutation replaces glycine with cysteine, impairing the intrinsic GTPase activity and preventing GAP-mediated hydrolysis, which locks KRAS in the active GTP-bound state. Adagrasib is a covalent inhibitor that binds specifically to the cysteine residue in the switch II pocket of the inactive GDP-bound form, trapping it and preventing its reactivation.
A patient with KRAS G12C-mutated NSCLC is starting adagrasib; what are the most common treatment-related adverse events (TRAEs) you must monitor for, and what are the specific criteria for managing hepatotoxicity?
Key Response
The most frequent TRAEs are gastrointestinal (diarrhea, nausea, vomiting) and fatigue. Hepatotoxicity is also common; per the study and prescribing labels, Grade 3 ALT/AST elevations require treatment interruption until recovery to Grade 1 or baseline, followed by a dose reduction or permanent discontinuation if recovery does not occur or recurs.
Considering the intracranial response data from the KRYSTAL-1 trial, how does the pharmacokinetic profile of adagrasib influence its utility in patients with untreated or progressing CNS metastases compared to other KRAS inhibitors?
Key Response
Adagrasib has demonstrated a high brain-to-plasma concentration ratio and clinically meaningful intracranial activity (intracranial ORR ~33% in sub-studies). This is attributed to its long half-life (~23 hours) and dose-dependent PK which maintains concentrations above the IC50, making it a viable option for patients with CNS involvement where other agents might have limited penetration.
In the context of evolving resistance to KRAS G12C inhibition, how should the findings of KRYSTAL-1 influence the sequencing of therapy and the integration of repeat molecular profiling at the time of progression?
Key Response
While adagrasib is effective, resistance inevitably develops through bypass signaling (e.g., MET amplification) or secondary KRAS mutations (e.g., Y96D). KRYSTAL-1 establishes a benchmark for second-line efficacy, but the high rate of acquired resistance necessitates repeat biopsy or liquid biopsy at progression to determine if a patient is eligible for combination trials or should transition to docetaxel-based regimens.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the pharmacodynamic rationale for the 600 mg twice-daily dosing of adagrasib used in KRYSTAL-1 versus a once-daily approach, specifically regarding the saturation of the KRAS protein synthesis-degradation cycle.
Key Response
KRAS G12C inhibitors only bind to the GDP-bound (inactive) state. Because new KRAS protein is synthesized continuously, twice-daily dosing maintains steady-state plasma concentrations that exceed the IC50 throughout the entire 24-hour interval, ensuring that newly synthesized KRAS is inhibited immediately upon entering the GDP-bound state, thereby maximizing target occupancy compared to once-daily dosing.
While the KRYSTAL-1 Phase 2 cohort showed an objective response rate of 43%, what limitations of this single-arm study design might a reviewer flag when assessing the generalizability of the survival outcomes compared to the current standard of care?
Key Response
Reviewers would flag the lack of a randomized control arm (e.g., vs. Docetaxel), which makes it difficult to account for selection bias in a heavily pre-treated population (median of 2 prior lines). Additionally, the use of a surrogate endpoint (ORR) as the primary outcome requires subsequent Phase 3 validation (like KRYSTAL-12) to confirm that these responses translate into a statistically significant improvement in overall survival.
How do the results of KRYSTAL-1 compare to the efficacy of Docetaxel plus Ramucirumab, and should current guidelines be updated to recommend adagrasib as the preferred second-line agent for KRAS G12C mutated NSCLC?
Key Response
The ORR for adagrasib (43%) and median PFS (6.5 months) compare favorably to the historical outcomes for docetaxel + ramucirumab (ORR ~23%, PFS ~4.5 months). NCCN guidelines currently list adagrasib as a preferred subsequent therapy (Category 2A). Full endorsement as the definitive 'preferred' agent often awaits Phase 3 head-to-head data, but the superior response rate and manageable safety profile already support its use over traditional chemotherapy in this molecular subset.
Clinical Landscape
Noteworthy Related Trials
CodeBreaK 100 Trial
Tested
Sotorasib 960 mg daily
Population
Patients with KRAS G12C-mutated NSCLC previously treated with chemotherapy or PD-1/PD-L1 inhibitors
Comparator
None (single-arm study)
Endpoint
Objective response rate (ORR)
CodeBreaK 200 Trial
Tested
Sotorasib 960 mg daily
Population
Patients with KRAS G12C-mutated NSCLC previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors
Comparator
Docetaxel
Endpoint
Progression-free survival (PFS)
KRYSTAL-12 Trial
Tested
Adagrasib 600 mg twice daily
Population
Patients with KRAS G12C-mutated NSCLC previously treated with platinum-based chemotherapy and immunotherapy
Comparator
Docetaxel
Endpoint
Progression-free survival (PFS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis